The novel idea of bioresorbable stent technology continues to fascinate the interventional community. This article aims to provide a concise and balanced overview of the available technology and clinical evidence. Both potentially positive and negative aspects of bioresorbable stents in different lesion subsets and clinical situations are discussed.

Cardiocenter 3rd Faculty of Medicine Charles University Prague University Hospital Kralovske Vinohrady Czech Republic

Zobrazit více v PubMed

Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc Interv. 2007;69(1):128–31. PubMed

Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779–97. PubMed

Onuma Y, Serruys PW, Perkins LE et al. Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122(22):2288–300. PubMed

Haude M, Erbel R, Erne P et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013;381(9869):836–44. PubMed

Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899–907. PubMed

Dudek D, Onuma Y, Ormiston JA et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention. 2012;7(9):1060–1. PubMed

Serruys PW, Onuma Y, Ormiston JA et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122(22):2301–12. PubMed

Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578–88. PubMed

Serruys PW, Onuma Y, Garcia-Garcia HM Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2013. [Epub ahead of print] PubMed

Onuma Y, Serruys PW, Gomez J et al. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheter Cardiovasc Interv. 2011;78(1):3–12. PubMed

Gomez-Lara J, Garcia-Garcia HM, Onuma Y et al. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv. 2010;3(11):1190–8. PubMed

Garcia-Garcia HM, Gonzalo N, Pawar R et al. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. EuroIntervention. 2009;4(4):443–8. PubMed

Bruining N, de Winter S, Roelandt JR et al. Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study. JACC Cardiovasc Interv. 2010;3(4):449–56. PubMed

Brugaletta S, Gomez-Lara J, Bruining N et al. Head to head comparison of optical coherence tomography, intravascular ultrasound echogenicity and virtual histology for the detection of changes in polymeric struts over time: insights from the ABSORB trial. EuroIntervention. 2012;8(3):352–8. PubMed

Gomez-Lara J, Radu M, Brugaletta S et al. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011;4(9):992–1001. PubMed

Brugaletta S, Gogas BD, Garcia-Garcia HM et al. Vascular compliance changes of the coronary vessel wall after bioresorbable vascular scaffold implantation in the treated and adjacent segments. Circ J. 2012;76(7):1616–23. PubMed

Farooq V, Gomez-Lara J, Brugaletta S et al. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. 2012;79(6):880–8. PubMed

Gomez-Lara J, Diletti R, Brugaletta S et al. Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. EuroIntervention. 2012;8(2):214–24. PubMed

Muramatsu T, Onuma Y, Garcia-Garcia HM et al. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovasc Interv. 2013;6(3):247–57. PubMed

Wiebe J, Mollmann H, Most A et al. Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold. Clin Res Cardiol. 2014;103(2):141–8. PubMed

Kocka V, Lisa L, Tousek P et al. ST elevation myocardial infarction treated with bioresorbable vascular scaffold: rationale and first cases. Eur Heart J. 2013;34(27):2073. PubMed

Kajiya T, Liang M, Sharma RK et al. Everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with ST-segment elevation myocardial infarction (STEMI) EuroIntervention. 2013;9(4):501–4. PubMed

La Manna A, Ohno Y, Attizzani GF, Tamburino C. Successful retrograde recanalization of chronic total coronary occlusion with multiple bioresorbable vascular scaffolds (‘full polymer jacket’): initial experience and rationale. Eur Heart J. 2013;34(37):2925. PubMed

Grundeken MJ, Kraak RP, de Bruin DM, Wykrzykowska JJ. Three-dimensional optical coherence tomography evaluation of a left main bifurcation lesion treated with ABSORB(R) bioresorbable vascular scaffold including fenestration and dilatation of the side branch. Int J Cardiol. 2013;168(3):e107–8. PubMed

Ong PJ, Jafary FH, Ho HH. “First-in-man„ use of bioresorbable vascular scaffold in saphenous vein graft. EuroIntervention. 2013;9(1):165. PubMed

Ribichini F, Pighi M, Faggian G, Vassanelli C. Bioresorbable vascular scaffolds in cardiac allograft vasculopathy: a new therapeutic option. Am J Med. 2013;126(11):e11–4. PubMed

Nieman K, Serruys PW, Onuma Y et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) J Am Coll Cardiol. 2013;62(19):1813–4. PubMed

Okamura T, Onuma Y, Garcia-Garcia HM et al. 3-Dimensional optical coherence tomography assessment of jailed side branches by bioresorbable vascular scaffolds: a proposal for classification. JACC Cardiovasc Interv. 2010;3(8):836–44. PubMed

Okamura T, Serruys PW, Regar E. Cardiovascular flashlight. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Eur Heart J. 2010;31(17):2179. PubMed

Farooq V, Onuma Y, Radu M et al. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. EuroIntervention. 2011;7(3):386–99. PubMed

Nishio S, Kosuga K, Igaki K et al. Long-term (>10 Years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;125(19):2343–53. PubMed